Director Emma Reeve of PTC Therapeutics exercised 10,000 stock options and sold the underlying shares for approximately $795,000, reducing her direct holdings to 6,666 shares according to SEC Form 4 filing. The sale represented 60.00% of Reeve’s direct holdings, marking a significant decrease in her exposure to PTC Therapeutics. Shares were priced at $79.50 for this transaction, with a one-year total return of 83.00%. PTC Therapeutics generates revenue through treatments for rare genetic disorders, operating a biopharmaceutical business model focused on drug discovery and global commercialization. Reeve’s recent sale may reflect an attempt to secure recent gains rather than escape a struggling business.

Despite rising Erysdi sales, Translarna sales at PTC Therapeutics are declining. In the third quarter of 2025, total revenue grew 7% year over year to $211 million, with royalty revenue from Roche for Evrysdi sales increasing. Reeve’s stock activity aligns with a pattern of reducing holdings through option-related sales. The company focuses on developing therapies for rare diseases, leveraging collaborations for growth and market differentiation. The latest sale by Reeve could be a strategic move to capitalize on recent stock gains for PTC Therapeutics.

Read more at Nasdaq: A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000